This oncology biotech advancing targeted therapies reported a notable insider sale amid ongoing clinical-stage development.

Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.

Gossamer Bio’s latest analyst update leaves the model fair value unchanged at US$4.46 per share and highlights an underweight ...

While Bio-Techne stock has underperformed the broader market over the past year, analysts remain moderately bullish about its ...

Bluebird Bio has three approved gene-editing therapies: Zynteglo, Skysona, and Lyfgenia. The most important of this trio, and the latest to earn approval (it did so in December), is Lyfgenia, which ...

Bluebird has repeatedly been floated as a possible buyout target by investors this year. Three key issues seem to be fueling this speculation: Bluebird scored two approvals from the Food and Drug ...

Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...

TELA Bio TELA shares are trading lower after the company priced a 4.75 million share offering at $9.50 per share. What Happened: On Tuesday after market closure, TELA Bio announced a public offering ...